# Morbilliform Drug Eruptions and the DRESS Syndrome

## Introduction

Drug eruptions are among the most common reasons for inpatient dermatology consultation. Morbilliform (exanthematous) drug eruptions represent the most frequent cutaneous adverse drug reaction, while Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome represents a severe, potentially life-threatening systemic hypersensitivity reaction. Distinguishing between these entities and recognizing the features that mandate urgent intervention are essential clinical skills.

## Morbilliform Drug Eruptions

### Epidemiology and Pathogenesis

Morbilliform drug eruptions account for **75 to 95% of all cutaneous drug reactions**, with an incidence of 1 to 5% of first-time drug exposures that is higher with certain drugs (aminopenicillins 5 to 10%, sulfonamides 3 to 6%). They represent a **type IVb delayed hypersensitivity reaction** mediated by drug-specific CD4+ T cells releasing Th2 cytokines (IL-4, IL-5, IL-13). The typical **onset** is **5 to 14 days** after initiation of the culprit drug with first exposure, though onset can occur within 1 to 2 days on re-exposure.

### Common Culprit Drugs

The most common culprit drugs include antibiotics (aminopenicillins such as amoxicillin, sulfonamides such as TMP-SMX, cephalosporins, and quinolones), anticonvulsants (phenytoin, carbamazepine, lamotrigine, which can also cause DRESS and SJS, making clinical distinction critical), allopurinol, NSAIDs, and antineoplastic agents. A notable clinical scenario is the **amoxicillin-EBV interaction**: 70 to 100% of patients with acute EBV mononucleosis develop a morbilliform eruption when given aminopenicillins. This is not a true drug allergy and does not contraindicate future penicillin use.

### Clinical Features

The eruption consists of symmetrically distributed, **erythematous macules and papules** that often coalesce into patches, beginning on the trunk and spreading to the extremities. **Pruritus** is common. The face, palms, and soles may be involved but are not the predominant sites. **Mucous membranes are spared**, and there are **no systemic symptoms** (no fever, no organ involvement), which is what distinguishes a simple morbilliform eruption from DRESS. The eruption may progress despite drug discontinuation before resolving over 1 to 2 weeks, and fine desquamation may occur during resolution.

### Diagnosis

The diagnosis is clinical, based on temporal correlation with drug exposure and characteristic morphology. No specific laboratory test exists; eosinophilia is mild or absent (unlike DRESS). Skin biopsy, if needed, shows **interface dermatitis with eosinophils** in the superficial dermis, and necrotic keratinocytes may be present but are sparse. Drug provocation testing and patch testing may help identify the culprit drug retrospectively but are not routinely performed acutely.

### Management

The suspected drug should be **discontinued** when possible and alternatives identified. **Symptomatic treatment** with medium-potency topical corticosteroids and oral antihistamines for pruritus is usually sufficient. The eruption is **self-limited**, resolving within 1 to 2 weeks after drug cessation. The reaction should be documented in the medical record, and the patient counseled to avoid the culprit drug in the future. In some clinical scenarios, **"treating through"** the eruption while continuing the drug is acceptable (for example, a morbilliform eruption to amoxicillin in a patient without EBV), with close monitoring for progression to DRESS or SJS.

### Red Flags Suggesting Progression Beyond Simple Morbilliform Eruption

Several features should raise concern for DRESS, SJS/TEN, or other severe drug reactions: **facial edema**, **fever above 38.5 C**, **mucous membrane involvement**, **skin pain or tenderness** rather than itch, **targetoid lesions**, vesicles, or bullae, **lymphadenopathy**, and **laboratory abnormalities** (eosinophilia, atypical lymphocytes, elevated transaminases). Any of these findings warrants immediate reassessment.

<image>Clinical photographs comparing a simple morbilliform drug eruption showing symmetric erythematous macules and papules on the trunk without mucosal involvement versus early DRESS syndrome showing facial edema, confluent erythema, and periorbital swelling</image>

## DRESS Syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms)

### Overview

Also known as **Drug-Induced Hypersensitivity Syndrome (DIHS)**, DRESS is a severe, potentially fatal systemic hypersensitivity reaction with a **mortality rate of 5 to 10%**. It is characterized by the triad of a **cutaneous eruption**, **hematologic abnormalities** (eosinophilia and/or atypical lymphocytosis), and **internal organ involvement**. DRESS is distinguished by a **longer latency period** (2 to 8 weeks) than simple morbilliform eruptions and a **prolonged, relapsing course**.

### Pathogenesis

The pathogenesis involves a complex interplay of **drug-specific T-cell activation**, **HHV-6 reactivation**, and **regulatory T-cell deficiency**. The drug or its reactive metabolites activate CD4+ and CD8+ T cells. **HHV-6 reactivation** occurs in 40 to 60% of DRESS cases and correlates with more severe organ involvement, representing a defining feature of the DIHS concept. Other herpesvirus reactivations (HHV-7, EBV, CMV) may also occur sequentially. **Oligoclonal T-cell expansion** targets both drug antigens and viral antigens through molecular mimicry. Genetic susceptibility involves strong **HLA associations** with specific drug-HLA pairings: **carbamazepine** with HLA-A*31:01 (European) and HLA-B*15:02 (associated more with SJS in Southeast Asian populations), **allopurinol** with HLA-B*58:01, **dapsone** with HLA-B*13:01, and **abacavir** with HLA-B*57:01 (hypersensitivity, not classic DRESS).

### Common Culprit Drugs

The classic culprits are the **aromatic anticonvulsants**: carbamazepine, phenytoin, lamotrigine, and phenobarbital, with 40 to 58% cross-reactivity between these agents. **Allopurinol** is the most common non-anticonvulsant cause. Other culprits include **sulfonamides** (especially dapsone), **vancomycin**, **minocycline**, and **abacavir**.

| Feature | Morbilliform Drug Eruption | DRESS Syndrome |
|---------|---------------------------|----------------|
| Latency | 5–14 days | 2–8 weeks |
| Fever | Absent | High (>38.5°C) |
| Facial edema | Absent | Characteristic |
| Organ involvement | None | Liver (60–80%), kidney, lung, heart |
| Eosinophilia | Absent or mild | Marked (>1500/µL in 60–90%) |
| Lymphadenopathy | Absent | Present (50–70%) |
| Duration | Self-limited (1–2 weeks) | Prolonged, relapsing (weeks to months) |
| Mortality | None | 5–10% |
| HHV-6 reactivation | No | Yes (40–60%) |

### Clinical Features

The **latency** is **2 to 8 weeks** after drug initiation, longer than other drug reactions. The **cutaneous eruption** is a widespread morbilliform eruption that may become infiltrated, edematous, or purpuric, and **facial edema** (especially periorbital) is highly characteristic. **Fever** is typically high (above 38.5 C) and is often the initial symptom. **Lymphadenopathy** is generalized in 50 to 70% of cases. **Hematologic abnormalities** include **eosinophilia** (above 1500/microL in 60 to 90%), **atypical lymphocytosis** (resembling mononucleosis), and leukocytosis.

**Organ involvement** occurs in order of frequency. The **liver** (60 to 80%) is most commonly affected, with hepatitis ranging from mild transaminase elevation to fulminant hepatic failure, the leading cause of DRESS mortality. The **kidney** (10 to 30%) may show interstitial nephritis, proteinuria, and elevated creatinine. The **lung** (5 to 25%) can develop interstitial pneumonitis or pleural effusion. The **heart** (2 to 10%) may develop myocarditis or pericarditis, which can present weeks after cutaneous resolution. The **thyroid** frequently develops autoimmune thyroiditis as a delayed sequela months after DRESS resolution. Pancreatic and CNS involvement are less common but reported.

### Diagnostic Criteria (RegiSCAR Scoring System)

The RegiSCAR scoring system evaluates fever above 38.5 C, enlarged lymph nodes (at least 2 sites, greater than 1 cm), eosinophilia (above 700/microL or above 10% if leukopenia), atypical lymphocytes, skin involvement (above 50% BSA), organ involvement (at least 1 organ), resolution longer than 15 days, and a negative workup for other causes (ANA, blood cultures, hepatitis serology). Score categories are: no case (below 2), possible (2 to 3), probable (4 to 5), and definite (above 5).

### Management

#### Acute Management

**Immediate discontinuation of the culprit drug** is the single most important intervention. **Systemic corticosteroids** (prednisone 0.5 to 1 mg/kg/day) are used for moderate-to-severe DRESS with a prolonged taper over **8 to 12 weeks minimum**, as rapid taper frequently causes relapse. Monitoring for rebound flare and herpesvirus reactivation (checking HHV-6 PCR) is essential. **Cyclosporine** (3 to 5 mg/kg/day) is increasingly used for steroid-refractory DRESS or as a steroid-sparing agent. Supportive care includes IV fluids, nutritional support, and wound care for skin.

#### Monitoring

During the acute phase, daily monitoring includes CBC with differential, hepatic panel, renal function, and urinalysis. During the taper, weekly then monthly monitoring continues with the same labs plus thyroid function tests. **Thyroid function** should be monitored for at least **12 months** after DRESS resolution, as hypothyroidism is the most common delayed autoimmune sequela. **Cardiac monitoring** with echocardiogram is warranted for any cardiac symptoms, as myocarditis can present weeks after skin resolution. HHV-6, CMV, and EBV PCR testing should be obtained if worsening occurs despite drug withdrawal or if the course is atypical.

<image>Flowchart for DRESS syndrome workup and management showing initial evaluation with labs and RegiSCAR scoring, acute management with drug withdrawal and systemic corticosteroids with slow taper schedule, and long-term monitoring timeline for thyroid function, cardiac screening, and herpesvirus reactivation over 12 months</image>

### Long-Term Considerations

**Cross-reactivity** of 40 to 58% exists among aromatic anticonvulsants (phenytoin, carbamazepine, phenobarbital), and all structurally related drugs should be avoided. **Family screening** is important because first-degree relatives of patients with aromatic anticonvulsant DRESS have a 25% risk due to shared slow acetylator phenotype. **HLA testing before drug initiation** is recommended for specific populations: HLA-B*58:01 before allopurinol in Southeast Asian and African American patients, HLA-A*31:01 before carbamazepine in European and Japanese patients, and HLA-B*57:01 before abacavir (standard of care). The culprit drug and the nature of the reaction (DRESS, not simple allergy) should be clearly documented in the medical record.

| Drug | HLA Allele | Population | Reaction |
|------|-----------|-----------|----------|
| Carbamazepine | HLA-B*15:02 | Southeast Asian | SJS/TEN |
| Carbamazepine | HLA-A*31:01 | European, Japanese | DRESS |
| Allopurinol | HLA-B*58:01 | Southeast Asian, African American | DRESS/SJS |
| Abacavir | HLA-B*57:01 | All (standard of care) | Hypersensitivity |
| Dapsone | HLA-B*13:01 | Southeast Asian | DRESS |

## Key Clinical Pearls

Facial edema is the clinical feature most suggestive of DRESS and distinguishes it from simple morbilliform eruption. DRESS has a 2 to 8 week latency, much longer than morbilliform eruptions (5 to 14 days) or SJS/TEN (4 to 28 days). Herpesvirus reactivation (especially HHV-6) is integral to DRESS pathogenesis and may drive organ damage. The corticosteroid taper must be prolonged (8 to 12 or more weeks) because rapid taper causes relapse in over 50% of cases. Thyroid function should be monitored for at least 12 months post-DRESS, as autoimmune thyroiditis is the most common delayed sequela.

## References

1. Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction — results from the prospective RegiSCAR study. *Br J Dermatol*. 2013;169(5):1071-1080.
2. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. *Allergol Int*. 2006;55(1):1-8.
3. Cho YT, Yang CW, Chu CY. Drug reaction with eosinophilia and systemic symptoms (DRESS): an interplay among drugs, viruses, and immune system. *Int J Mol Sci*. 2017;18(6):1243.
4. Phillips EJ, Chung WH, Garon SL, Pirmohamed M. Drug hypersensitivity: pharmacogenetics and clinical syndromes. *J Allergy Clin Immunol*. 2018;141(2):S545-S558.